We provide you with 20 years of free, institutional-grade data for VERV stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VERV. Explore the full financial landscape of VERV stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-05-14 | 1840574 | VERV | 10-Q | Url |
| 2025-02-27 | 1840574 | VERV | 10-K | Url |
| 2024-11-05 | 1840574 | VERV | 10-Q | Url |
| 2024-08-08 | 1840574 | VERV | 10-Q | Url |
| 2024-05-08 | 1840574 | VERV | 10-Q | Url |
| 2024-02-27 | 1840574 | VERV | 10-K | Url |
| 2023-11-07 | 1840574 | VERV | 10-Q | Url |
| 2023-08-10 | 1840574 | VERV | 10-Q | Url |
| 2023-05-15 | 1840574 | VERV | 10-Q | Url |
| 2023-03-02 | 1840574 | VERV | 10-K | Url |
| 2022-11-07 | 1840574 | VERV | 10-Q | Url |
| 2022-08-09 | 1840574 | VERV | 10-Q | Url |
| 2022-05-10 | 1840574 | VERV | 10-Q | Url |
| 2022-03-14 | 1840574 | VERV | 10-K | Url |
| 2021-11-10 | 1840574 | VERV | 10-Q | Url |
| 2021-08-12 | 1840574 | VERV | 10-Q | Url |
| 2021-05-28 | 1840574 | VERV | S-1 | Url |
Verve Therapeutics(NASDAQ:VERV) 
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
Share this website to your friends
The information provided in this report about VERV stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.